AbbVie should report strong Q3 2024 results next week and increase the full-year guidance. Explore more details here.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

David Risinger, an analyst from Leerink Partners, maintained the Hold rating on AbbVie (ABBV – Research Report). The associated price ...

In a report released today, Christopher Raymond from Piper Sandler maintained a Buy rating on AbbVie (ABBV – Research Report), with a ...

AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

Equities research analysts at Zacks Research reduced their Q3 2024 earnings estimates for AbbVie in a research note issued on ...

After being diagnosed with Parkinson's disease at 50, Janice Hall felt her tremors get worse. Three years after being diagnosed she could "feel a kind of fluttering" that her medication could not stop ...

As Kamala Harris crisscrossed battleground states with ultra-right warmonger Liz Cheney, Vermont Senator Bernie Sanders ...

The U.S. Food and Drug Administration has approved AbbVie's Vyalev (foscarbidopa and foslevodopa) for adults living with ...

Piramal Pharma Limited (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceuticals and wellness company, today announced ...

Plus: Groupon cofounder’s healthcare venture, investments in CAR-T therapies and the upcoming Forbes Healthcare Summit.